Cited by 3,421Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 303 of the 309 references it cites were found in a registry or an index.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Open access

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.·2016·Annals of Oncology

DOI 10.1093/annonc/mdw235

Open this paper in CoChat — free account Open PDF

Abstract

Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw235

Cites

303 of 303 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova‐Foucher, E., Lortet‐Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,243
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citation
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
Fong, Y., Fortner, J. G., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,722

Flagged first, then by citations

Show all 309 references

6 of the 309 references couldn’t be matched to a known paper.

Research works printed but not linked: 6

Stintzing, 2013, Analysis of KRAS/NRAS and BRAF mutations in FIRE-3, Eur J Cancer, 49
Venook, 2014, J Clin Oncol, 32
Collettini, 2012, Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates, Rofo, 184, 316
Lenz, 2014, Ann Oncol, 25
Garcia Alfonso, 2014, Ann Oncol, 25
Cascinu, 2015, Eur J Cancer, 51

Sorted by citations

Items 101–200 of 1,003

Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
Krebs, M., Malapelle, U., André, F., Paz‐Ares, L., Schüler, M., Thomas, D. M., Vainer, G. W., Yoshino, T., & Rolfo, C. D. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.4457 · Cited by 130
Self-citation
Current advancements and future perspectives of immunotherapy in colorectal cancer research
Kishore, C., & Bhadra, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173819 · Cited by 126
Pattern, Stage, and Time of Recurrent Colorectal Cancer After Curative Surgery
Guraya, S. Y. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.01.003 · Cited by 125
Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
Yaeger, R. D., Kotani, D., Mondaca, S., Parikh, A. R., Bando, H., Seventer, E. E. V., Taniguchi, H., Zhao, H., Thant, C. N., de Stanchina, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2004 · Cited by 130
Self-citation
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
Roviello, G., D’Angelo, A., Petrioli, R., Roviello, F., Cianchi, F., Nobili, S., Mini, E., & Lavacchi, D. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100795 · Cited by 129
CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer
Heras, S. C. L., & Martinez‐Balibrea, E. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i42.4738 · Cited by 128
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
Bilen, M. A., Shabto, J. M., Martini, D. J., Liu, Y., Lewis, C. M., Collins, H., Akce, M., Kissick, H. T., Carthon, B. C., Shaib, W. L., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6073-7 · Cited by 126
The global challenge of colorectal cancer
Guren, M. G. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30329-2 · Cited by 123
Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
de Miguel‐Pérez, D., Martínez, A. R., Palomo, A. O., Ureña, M. D., Puche, J. L. G., Robles-Remacho, A., Hernández, J. E., Lorente, J. A., Ortega, F. G., & Serrano, M. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-60212-1 · Cited by 131
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis
Tosi, F., Magni, E., Amatu, A., Mauri, G., Bencardino, K. B., Truini, M., Veronese, S. M., Carlis, L. G. D., Ferrari, G. C., Nichelatti, M., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.004 · Cited by 122
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study
Cremolini, C., Morano, F., Moretto, R., Berenato, R., Tamborini, E., Perrone, F., Rossini, D., Gloghini, A., Busico, A., Zucchelli, G., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx546 · Cited by 126
Self-citation
Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study
Reichling, C., Taı̈eb, J., Dérangère, V., Klopfenstein, Q., Malicot, K. L., Gornet, J., Bécheur, H., Fein, F., Cojocarasu, O., Kaminsky, M. C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319292 · Cited by 124
Self-citation
Liver-First Approach for Synchronous Colorectal Metastases: Analysis of 7360 Patients from the LiverMetSurvey Registry
Giuliante, F., Viganò, L., Rose, A. M. D., Mirza, D. F., Lapointe, R. W., Kaiser, G. M., Barroso, E., Ferrero, A., Isoniemi, H., López‐Ben, S., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10220-w · Cited by 121
Self-citation
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2409 · Cited by 115
Self-citation
Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials
Fontana, E., Eason, K., Cervantes, A. M. R., Salazar, R., & Sadanandam, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz052 · Cited by 119
Self-citation
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Doleschel, D., Hoff, S., Koletnik, S., Rix, A., Zopf, D., Kiessling, F., & Lederle, W. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02043-0 · Cited by 114
Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group
Nieuwenhuizen, S., Puijk, R. S., van den Bemd, B. A. T., Aldrighetti, L. A., Arntz, M. J., van den Boezem, P. B., Bruynzeel, A. M. E., Burgmans, M. C., COBELLI, F. D., Coolsen, M. M. E., et al. (2020) · Cancers · doi:10.3390/cancers12071779 · Cited by 117
CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours
Venturini, M., Cariati, M., Marra, P., Masala, S. A., Pereira, P. L., & Carrafiello, G. (2020) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-020-02432-6 · Cited by 116
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Rugo, H. S., Tolaney, S. M., Loirat, D., Punie, K., Bardia, A., Hurvitz, S. A., O’Shaughnessy, J., Cortés, J., Dieras, V. C., Carey, L., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00467-1 · Cited by 117
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
Normanno, N., Abate, R. E., Lambiase, M., Forgione, L., Cardone, C., Iannaccone, A., Sacco, A., Rachiglio, A. M., Martinelli, E., Rizzi, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx417 · Cited by 115
Self-citation
Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Osumi, H., Shinozaki, E., Yamaguchi, K., & Zembutsu, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-53711-3 · Cited by 114
Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives
Taı̈eb, J., André, T., & Auclin, É. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.02.002 · Cited by 115
Self-citation
Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study
Osterlund, P. J., Salminen, T., Soveri, L., Kallio, R., Kellokumpu, I., Lamminmäki, A., Halonen, P., Ristamäki, R., Lantto, E., Uutela, A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100049 · Cited by 114
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer
Pietrantonio, F., Morano, F., Corallo, S., Miceli, R., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Bergamo, F., Bianchi, A. S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1467 · Cited by 114
Self-citation
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better
Andrei, P., Battuello, P., Grasso, G., Rovera, E., Tesio, N., & Bardelli, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.007 · Cited by 116
Self-citation
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment
Thierry, A. R., Messaoudi, S. E., Mollévi, C., Raoul, J., Guimbaud, R., Pezet, D., Artru, P., Assénat, E., Borg, C., Mathonnet, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx330 · Cited by 114
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer
Cremolini, C., Antoniotti, C., Lonardi, S., Aprile, G., Bergamo, F., Masi, G., Grande, R., Tonini, G., Mescoli, C., Cardellino, G. G., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5314 · Cited by 116
Self-citation
Evolving role of regorafenib for the treatment of advanced cancers
Grothey, A. F., Blay, J., Pavlakis, N., Yoshino, T., & Bruix, J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101993 · Cited by 116
Self-citation
Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer
Wei, R., Zhou, Y., Li, C., Rychahou, P. G., Zhang, S., Titlow, W. B., Bauman, G., Wu, Y., Liu, J., Wang, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2778 · Cited by 112
Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up
Scorsetti, M., Comito, T., Clerici, E., Franzese, C., Tozzi, A., Iftode, C., Brina, L. D., Navarria, P., Mancosu, P., Reggiori, G., et al. (2018) · Radiation Oncology · doi:10.1186/s13014-018-1185-9 · Cited by 111
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Bianchi, A. S., Tomasello, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01254 · Cited by 116
Radiomics of Liver Metastases: A Systematic Review
Fiz, F., Viganò, L., Gennaro, N., Costa, G., Bella, L. L., Boichuk, A., Cavinato, L., Sollini, M., Politi, L. S., Chiti, A., et al. (2020) · Cancers · doi:10.3390/cancers12102881 · Cited by 114
Thermal Ablation of Lung Tumors: Focus on Microwave Ablation
Vogl, T., Nour-Eldin, N.-E. A., Albrecht, M. H., Kaltenbach, B., Hohenforst‐Schmidt, W., Lin, H., Panahi, B., Eichler, K., Gruber‐Rouh, T., & Roman, A. (2017) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/s-0043-109010 · Cited by 110
Next-generation sequencing: recent applications to the analysis of colorectal cancer
Vecchio, F. D., Mastroiaco, V., Marco, A. D., Compagnoni, C., Capece, D., Zazzeroni, F., Capalbo, C., Alesse, E., & Tessitore, A. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1353-y · Cited by 110
CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation
Lucatelli, P., Burrel, M., Guiu, B., Rubeis, G. D., van Delden, O. M., & Helmberger, T. K. (2021) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-021-02968-1 · Cited by 110
ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer
Wong, T. L., Loh, J.-J., Lu, S., Yan, H. H. N., Siu, H. C., Ren, X., Chan, D., Kam, M. J., Zhou, L., Tong, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38581-8 · Cited by 115
The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials
Hervieu, C., Christou, N., Battu, S., & Mathonnet, M. (2021) · Cancers · doi:10.3390/cancers13051092 · Cited by 116
Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines : mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx
Loriot, M., Ciccolini, J., Thomas, F., Guellec, C. B., Royer, B., Milano, G. A., Picard, N., Becquemont, L., Verstuyft, C., Narjoz, C., et al. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.02.001 · Cited by 107
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Bruun, J., Kryeziu, K., Eide, P. W., Moosavi, S. H., Eilertsen, I. A., Langerud, J., Røsok, B. I., Totland, M. Z., Brunsell, T. H., Pellinen, T. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3637 · Cited by 111
Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer
Miyamoto, Y., Suyama, K., & Baba, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040752 · Cited by 110
Recent developments in the treatment of metastatic colorectal cancer
Loree, J. M., & Kopetz, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017714997 · Cited by 108
Percutaneous thermal ablation of lung tumors – Radiofrequency, microwave and cryotherapy: Where are we going?
Palussière, J., Catena, V., & Buy, X. (2017) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2017.07.003 · Cited by 105
Chemoprevention of Colorectal Cancer by Dietary Compounds
Costea, T., Hudiță, A., Ciolac, O.-A., Gălățeanu, B., Ginghină, O., Costache, M., Ganea, C., & Mocanu, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123787 · Cited by 109
Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial
Radosevic, A., Quesada, R., Serlavos, C., Sánchez, J., Zugazaga, A., Sierra, A., Coll, S., Busto, M., Aguilar, G., Flores, D., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-03802-x · Cited by 105
Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer
Dey, A., Mitra, A., Pathak, S., Prasad, S. V., Sun-Zhang, A., Zhang, H., Sun, X., & Banerjee, A. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231178403 · Cited by 108
Class 1, 2, and 3 BRAF -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization
Schirripa, M., Biason, P., Lonardi, S., Pella, N., Pino, M. S., Urbano, F., Antoniotti, C., Cremolini, C., Corallo, S., Pietrantonio, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0311 · Cited by 102
Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases
Siebenhüner, A. R., Güller, U., & Warschkow, R. (2020) · BMC Cancer · doi:10.1186/s12885-020-6710-1 · Cited by 102
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer
Strickler, J. H., Yoshino, T., Graham, R. P., Siena, S., & Bekaii‐Saab, T. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.8196 · Cited by 106
Self-citation
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
Garralda, E., Sukari, A. W., Lakhani, N. J., Patnaik, A., Lou, Y., Im, S., Golan, T., Geva, R., Wermke, M., de Miguel, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100639 · Cited by 105
Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review
García‐Foncillas, J., Alba, E., Aranda, E., Díaz‐Rubio, E., López‐López, R., Tabernero, J. M., & Vivancos, A. P. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx501 · Cited by 102
Self-citation
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells
Mangiapane, L. R., Nicotra, A., Turdo, A., Gaggianesi, M., Bianca, P., Franco, S. D., Sardina, D. S., Veschi, V., Signore, M., Beyes, S., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323553 · Cited by 102
Immunotherapy for colorectal cancer: where are we heading?
Basile, D., Garattini, S. K., Bonotto, M., Ongaro, E., Casagrande, M., Cattaneo, M., Fanotto, V., Carlo, E. D., Loupakis, F., Urbano, F., et al. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1315405 · Cited by 100
Carbon dots for cancer nanomedicine: a bright future
Bayda, S., Amadio, E., Cailotto, S., Frión-Herrera, Y., Perosa, A., & Rizzolio, F. (2021) · Nanoscale Advances · doi:10.1039/d1na00036e · Cited by 99
c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival
Lee, S. J., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., Park, Y. S., & Kim, S. T. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.02.013 · Cited by 98
Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study
Isambert, N., Hervieu, A., Rébé, C., Hennequin, A., Borg, C., Zanetta, S., Chevriaux, A., Richard, C., Dérangère, V., Limagne, E., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1474319 · Cited by 96
Surgical Outcome and Prognostic Stratification for Pulmonary Metastasis From Colorectal Cancer
Okumura, T., Boku, N., Hishida, T., Ohde, Y., Sakao, Y., Yoshiya, K., Higashiyama, M., Hyodo, I., Mori, K. P., & Kondo, H. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.03.021 · Cited by 95
Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
Nadiradze, G., Horvath, P., Sautkin, Y., Archid, R., Weinreich, F., Königsrainer, A., & Reymond, M. A. (2019) · Cancers · doi:10.3390/cancers12010034 · Cited by 98
Immunoscore and its introduction in clinical practice
Galon, J., & Lanzi, A. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03249-5 · Cited by 96
Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies
Frank, M. H., Wilson, B. J., Gold, J. S., & Frank, N. Y. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.080 · Cited by 102
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
Vitiello, P. P., Cardone, C., Martini, G., Ciardiello, D., Belli, V., Matrone, N., Barra, G., Napolitano, S., Della Corte, C., Turano, M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1035-0 · Cited by 96
Self-citation
Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation
Sivesgaard, K., Larsen, L. P., Sørensen, M., Kramer, S., Schlander, S., Amanavicius, N., Bharadwaz, A., Nielsen, D. T., Mortensen, F. V., & Pedersen, E. M. (2018) · European Radiology · doi:10.1007/s00330-018-5469-0 · Cited by 94
MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors
Svrcek, M., Lascols, O., Cohen, R., Collura, A., Jonchère, V., Fléjou, J.-F., Buhard, O., & Duval, A. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.12.008 · Cited by 90
DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update
Henricks, L. M., Opdam, F. L., Beijnen, J. H., Cats, A., & Schellens, J. H. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx411 · Cited by 93
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial
von Einem, J. C., Guenther, C., Volk, H., Grütz, G., Hirsch, D. D., Salat, C., Stoetzer, O. J., Nelson, P. J., Michl, M., Modest, D. P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32230 · Cited by 93
Self-citation
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer—central evaluation of FIRE-3
Modest, D. P., Denecke, T., Pratschke, J., Ricard, I., Lang, H., Bemelmans, M. H. A., Becker, T., Rentsch, M., Seehofer, D., Bruns, C. J., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.028 · Cited by 91
Self-citation
Electrolyte Disorders Induced by Antineoplastic Drugs
Verzicco, I., Regolisti, G., Quaini, F., Bocchi, P., Brusasco, I., Ferrari, M. L., Passeri, G., Cannone, V., Coghi, P., Fiaccadori, E., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00779 · Cited by 94
Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance
Ebrahimi, N., Afshinpour, M., Fakhr, S. S., Kalkhoran, P. G., Shadman-Manesh, V., Adelian, S., Beiranvand, S., Rezaei‐Tazangi, F., Khorram, R., Hamblin, M. R., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103920 · Cited by 90
Regorafenib: A Review in Metastatic Colorectal Cancer
Dhillon, S. (2018) · Drugs · doi:10.1007/s40265-018-0938-y · Cited by 90
EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
Martini, G., Cardone, C., Vitiello, P. P., Belli, V., Napolitano, S., Troiani, T., Ciardiello, D., Corte, C. M. D., Morgillo, F., Matrone, N., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0539 · Cited by 90
Self-citation
DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
Wigle, T. J., Tsvetkova, E. V., Welch, S. A., & Kim, R. B. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11050199 · Cited by 90
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies
Mauri, G., Pizzutilo, E. G., Amatu, A., Bencardino, K. B., Palmeri, L., Bonazzina, E. F., Tosi, F., Stella, G. C., Burrafato, G., Scaglione, F., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.006 · Cited by 90
Self-citation
How we treat metastatic colorectal cancer
Falco, V. D., Napolitano, S., Roselló, S., Huerta, M., Cervantes, A. M. R., Ciardiello, F., & Troiani, T. (2019) · ESMO Open · doi:10.1136/esmoopen-2020-000813 · Cited by 94
Self-citation
All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide
Innocenti, F., Mills, S. C., Sanoff, H. K., Ciccolini, J., Lenz, H., & Milano, G. A. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00553 · Cited by 89
Targeting KRAS in Cancer: Promising Therapeutic Strategies
Mustachio, L. M., Chelariu-Raicu, A., Székvölgyi, L., & Roszik, J. (2021) · Cancers · doi:10.3390/cancers13061204 · Cited by 93
“Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”
Papaccio, F., García-Micó, B., Gimeno-Valiente, F., Cabeza-Segura, M., Gambardella, V., Gutiérrez-Bravo, M. F., Alfaro‐Cervelló, C., Martínez‐Ciarpaglini, C., Rentero-Garrido, P., Zúñiga, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02591-z · Cited by 91
Self-citation
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
Carrato, A., Abad, A., Massutí, B., Grávalos, C., Escudero, P., Longo-Muñoz, F., Manzano, J.-L., Gómez, A., Safont, M. J., Gallego-Plazas, J., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.04.024 · Cited by 87
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
Modest, D. P., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A. O., von Weikersthal, L. F., Caca, K., Kretzschmar, A., Goekkurt, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01332 · Cited by 89
Self-citation
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
van de Haar, J., Ma, X., Ooft, S., van der Helm, P. W., Hoes, L. R., Mainardi, S., Pinato, D. J., Sun, K., Salvatore, L., Tortora, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02240-8 · Cited by 92
Strategies to tackle RAS-mutated metastatic colorectal cancer
Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86
Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx ® ): a placebo-controlled randomised phase II study (PLIANT)
Glimelius, B. L. G., Manojlovic, N. S., Pfeiffer, P., Mosidze, B., Kurteva, G. P., Karlberg, M., Mahalingam, D., Jensen, P. B., Kowalski, J. H., Bengtson, M. H., et al. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1398836 · Cited by 86
Self-citation
Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM
Vera, R., González‐Flores, E., Rubio, C., Urbano, J., Camps, M. V., Ciampi-Dopazo, J. J., Rincón, J. O., Macías, V. M., Braco, M. A. G., & Artacho, G. S. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02182-z · Cited by 87
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
Mauri, G., Arena, S., Siena, S., Bardelli, A., & Bianchi, A. S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.027 · Cited by 87
Self-citation
Tumour budding and its clinical implications in gastrointestinal cancers
Zlobec, I., Berger, M. D., & Lugli, A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0954-z · Cited by 86
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone
Glimelius, B. L. G., Stintzing, S., Marshall, J. L., Yoshino, T., & de Gramont, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102218 · Cited by 90
Self-citation
Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival
Sorrentino, C., D’Antonio, L., Fieni, C., Ciummo, S. L., & Carlo, E. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.778329 · Cited by 92
Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
Sawada, K., Nakamura, Y., Yamanaka, T., Kuboki, Y., Yamaguchi, D., Yuki, S., Yoshino, T., Komatsu, Y., Sakamoto, N., Okamoto, W., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.006 · Cited by 87
Self-citation
Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
Fondevila, F., Méndez‐Blanco, C., Fernández‐Palanca, P., González‐Gallego, J., & Mauriz, J. L. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0308-1 · Cited by 85
Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)
Helmberger, T. K., Golfieri, R., Pech, M., Pfammatter, T., Arnold, D., Cianni, R., Maleux, G. A., Munneke, G. J., Pellerin, O., Peynırcıoğlu, B., et al. (2020) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-020-02642-y · Cited by 85
Self-citation
Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-2): A Phase II, Two-Center, Single-Arm Clinical Trial
Meijerink, M. R., Ruarus, A. H., Vroomen, L. G. P. H., Puijk, R. S., Geboers, B., Nieuwenhuizen, S., van den Bemd, B. A. T., Nielsen, K., de Vries, J. J. J., van Lienden, K. P., et al. (2021) · Radiology · doi:10.1148/radiol.2021203089 · Cited by 87
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer
Smeby, J., Sveen, A., Merok, M. A., Danielsen, S. A., Eilertsen, I. A., Guren, M. G., Dienstmann, R., Nesbakken, A., & Lothe, R. A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy085 · Cited by 84
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice
Bekaii‐Saab, T., Kim, R. D., Kim, T. W., O’Connor, J. M., Strickler, J. H., Malka, D., Bianchi, A. S., Bi, F., Yamaguchi, K., Yoshino, T., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.11.002 · Cited by 83
Self-citation
Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer
Burness, C. B., & Duggan, S. T. (2016) · Drugs · doi:10.1007/s40265-016-0633-9 · Cited by 85
The safety and effectiveness of robot-assisted versus laparoscopic TME in patients with rectal cancer
Li, X., Wang, T., Yao, L., Hu, L., Jin, P., Guo, T., & Yang, K. (2017) · Medicine · doi:10.1097/md.0000000000007585 · Cited by 82
Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency
Bourdais, R., Rousseau, B., Pujals, A., Boussion, H., Joly, C., Guillemin, A., Baumgaertner, I., Neuzillet, C., & Tournigand, C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.027 · Cited by 83
Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis
Marques, R. P., Duarte, G. S., Sterrantino, C., Pais, H. L., Quintela, A., Martins, A. P., & Costa, J. N. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.08.006 · Cited by 85
Zebrafish Avatars towards Personalized Medicine—A Comparative Review between Avatar Models
Costa, B. F., Estrada, M. F., Mendes, R. V., & Fior, R. (2020) · Cells · doi:10.3390/cells9020293 · Cited by 87
Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A. P., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 87
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
Rossini, D., Antoniotti, C., Lonardi, S., Pietrantonio, F., Moretto, R., Antonuzzo, L., Boccaccino, A., Morano, F., Brugia, M., Pozzo, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00839 · Cited by 80
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update
Wang, F., Chen, G., Zhang, Z., Yuan, Y., Wang, Y., Gao, Y., Sheng, W., Wang, Z., Li, X., Yuan, X., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12639 · Cited by 91
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
García‐Foncillas, J., Tabernero, J. M., Élez, E., Aranda, E., Benavides, M., Camps, C., Lewintre, E. J., López‐López, R., Muinelo‐Romay, L., Montagut, C. O., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0293-5 · Cited by 84
Self-citation

Authors: Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W. J. G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T. J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H. J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., & Arnold, D.
Affiliations: Universitat de València (ES)
Hôpital Paul-Brousse (FR)
Ospedale Policlinico San Martino (IT)
Tel Aviv University (IL)
University of Turin (IT)
Northwestern Medicine (US)
Unified Szent István and Szent László Hospital (HU)
University of Campania "Luigi Vanvitelli" (IT)
Institut de Cancérologie de l'Ouest (FR)
Université Paris-Saclay (FR)
University of Pisa (IT)
Mayo Clinic (US)
Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
KU Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
Universidade de São Paulo (BR)
Klinikum Oldenburg (DE)
Ospedale Papa Giovanni XXIII (IT)
Chinese University of Hong Kong (HK)
University of Oxford (GB)
Aichi Cancer Center (JP)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Institute of Cancer Research (GB)
Bank of Cyprus Oncology Center (CY)
University of Ioannina (GR)
Odense University Hospital (DK)
Queen Elizabeth Hospital (AU)
Amsterdam UMC Location University of Amsterdam (NL)
University Hospital Magdeburg (DE)
University Hospital of Geneva (CH)
Institut Català d'Oncologia (ES)
Comprehensive Cancer Center Vienna (AT)
Martin Luther University Halle-Wittenberg (DE)
Vall d'Hebron Hospital Universitari (ES)
Universitair Ziekenhuis Leuven (BE)
Imperial College Healthcare NHS Trust (GB)
National Cancer Center Hospital East (JP)
Hôpital Européen Georges-Pompidou (FR)
ORCID: Cervantes, A.
Adam, R.
Sobrero, A.
Bardelli, A.
Benson, A.
Bodoky, G.
Ciardiello, F.
Douillard, J.-Y.
Ducreux, M.
Falcone, A.
Grothey, A.
Gruenberger, T.
Haustermans, K.
Heinemann, V.
Hoff, P.
Labianca, R.
Ma, B.
Maughan, T.
Muro, K.
Normanno, N.
Oyen, W.J.G.
Papamichael, D.
Pentheroudakis, G.
Pfeiffer, P.
Price, T.J.
Punt, C.
Ricke, J.
Salazar, R.
Schmoll, H.J.
Tabernero, J.
Tejpar, S.
Wasan, H.
Yoshino, T.
Zaanan, A.
Arnold, D.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 27
Issue: 8
Pages: 1386-1422
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdw235
OpenAlex: W2470575266
Cited by: 3,421
References: 309
Citations by year: 2026: 199 · 2025: 236 · 2024: 297 · 2023: 364 · 2022: 481 · 2021: 518 · 2020: 444 · 2019: 365 · 2018: 279 · 2017: 189 · 2016: 39
FWCI: 155.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1191 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Lirias (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
Funders: Cancer Research UK (13363)
National Institute for Health and Care Research (11/100/50)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, colorectal cancer, surgical resection of metastases, systemic therapy, multidisciplinary management, treatment decision-making, evidence-based recommendations
MeSH terms: Humans, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Guidelines as Topic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks